Retham Technologies is a biotech company that provides a diagnosis of heparin induced thrombocytopenia by enabling rapid HIT testing.
Retham Technologies has raised $4.8M in total funding. The most recent round was Grant. The last funding was announced in September 2026.
Retham Technologies's investors include National Institutes of Health, Golden Angels Investors, Talents Fund, SBIR Advance, Milwaukee Venture Partners.
Retham Technologies is headquartered in Wauwatosa, United States.
Retham Technologies is a biotech company that provides a diagnosis of heparin induced thrombocytopenia by enabling rapid HIT testing.
Retham Technologies is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Retham Technologies — Funding & Investors." VCBacked, September 15, 2026, https://www.vcbacked.co/company/retham-technologies. Accessed October 1, 2026.
VCBacked. (2026). Retham Technologies — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/retham-technologies
{{cite web |title=Retham Technologies — Funding & Investors |url=https://www.vcbacked.co/company/retham-technologies |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated